The First-of-its-Kind Comprehensive Immune Profile.

Immunotherapy is a relatively new way to treat cancer. This treatment method stimulates an immune response to cancer, similar to the way the body responds to and eliminates bacteria and viruses.

Oncologists and their patients have turned to immunotherapy in increasing numbers, and while a good portion of these patients may have received a test result indicating a likely response to immunotherapy, only about 30% of such patients have seen such a response (LEK Analysis). Researchers were unsure why current tests were not more accurate in predicting response.

Through a retrospective study of our assay using a research cohort of cancer specimens from Roswell Park Comprehensive Cancer Center, we found that one answer could be the high level of complexity of each person’s immune system – essentially, different people’s immune systems exhibit unique abnormalities that aren’t always identified by using a single biomarker. A more robust interrogation of multiple biomarkers provided more insight, and, by extension, a better understanding of a patient’s comprehensive immune profile and which therapeutic options might be best.

Better Measurements,
Less Guesswork.

This is why we created the OmniSeq Immune Report Card®. This unique and unprecedented report provides clinicians with a comprehensive immune profile of their patient, greatly improving their ability to select a personalized immunotherapy treatment based on their patient’s unique gene expression. For the first time, clinicians could also narrow the options of novel immunotherapy agents for a patient to consider.

This first-of-its-kind immune profile can help inform specific combinations of immunotherapy and clinical trial options. Clinicians receive a detailed interpretation of the Immune Report Card®, allowing them to make educated, informed decisions regarding appropriate treatments. Using a test such as the Immune Report Card® prior to the first course of immunotherapy can inform an entire treatment course, including first line considerations (and follow-on considerations in the case of progression). It is important to also consider what subsequent trials may or may not be available to a patient once they have proceeded with treatment with an immunotherapy drug.

Immunotherapy Actionability Percentage by Biomarker

Percentage, 100% = 167 Patients
(Pan-Histology)

  • High Expression of Other Immune Markers, but not PD-L1 High (IHC >50%) or Mutational Burden (MuB) High 48%
  • No Highly Expressed Markers (Immune Desert) 27%
  • Mutational Burden (MuB) High 12%
  • PD-L1 High (IHC >50%) 10%
  • MuB High & PD-L1 High (IHC >50%) 3%

Source: OmniSeq Initial Reference Population, 2017

Overall Response Rate (ORR) by Biomarker

Percentage, n = 158 Patients
(Lung Cancer Only)

  • High Expression of Other Immune Markers, but not PD-L1 High (IHC >50%) or Mutational Burden (MuB) High 16%
  • No Highly Expressed Markers (Immune Desert) 16%
  • Mutational Burden (MuB) High 32%
  • PD-L1 High (IHC >50%) 34%
  • MuB High & PD-L1 High (IHC >50%) 75%

Source: Bristol Myers Squibb Checkmate 026

Better Measurements,
Less Guesswork.

This is why we created the OmniSeq Immune Report Card®. This unique and unprecedented report provides clinicians with a comprehensive immune profile of their patient, greatly improving their ability to select a personalized immunotherapy treatment based on their patient’s unique gene expression. For the first time, clinicians could also narrow the options of novel immunotherapy agents for a patient to consider.

This first-of-its-kind immune profile can help inform specific combinations of immunotherapy and clinical trial options. Clinicians receive a detailed interpretation of the Immune Report Card®, allowing them to make educated, informed decisions regarding appropriate treatments. Using a test such as the Immune Report Card® prior to the first course of immunotherapy can inform an entire treatment course, including first line considerations (and follow-on considerations in the case of progression). It is important to also consider what subsequent trials may or may not be available to a patient once they have proceeded with treatment with an immunotherapy drug.

Immunotherapy Actionability Percentage by Biomarker

Percentage, 100% = 167 Patients
(Pan-Histology)

  • High Expression of Other Immune Markers, but not PD-L1 High (IHC >50%) or Mutational Burden (MuB) High 48%
  • No Highly Expressed Markers (Immune Desert) 27%
  • Mutational Burden (MuB) High 12%
  • PD-L1 High (IHC >50%) 10%
  • MuB High & PD-L1 High (IHC >50%) 3%

Source: OmniSeq Initial Reference Population, 2017

Overall Response Rate (ORR) by Biomarker

Percentage, n = 158 Patients
(Lung Cancer Only)

  • High Expression of Other Immune Markers, but not PD-L1 High (IHC >50%) or Mutational Burden (MuB) High 16%
  • No Highly Expressed Markers (Immune Desert) 16%
  • Mutational Burden (MuB) High 32%
  • PD-L1 High (IHC >50%) 34%
  • MuB High & PD-L1 High (IHC >50%) 75%

Source: Bristol Myers Squibb Checkmate 026

Download a sample of the Immune Report Card®

Specimen Requirements